Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies (SAFRAN)
Type I Interferon Excess in Autoimmune Diseases and Genetic Type I Interferonopathies
Systemic autoimmune diseases associated with type I interferon (IFN-I) dysregulation, such as systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type 1 interferonopathies are characterized by chronic and excession IFN-I signaling and production contributing to disease pathogenesis. Aberrant IFN-I production can be triggered through the activation of multiple signaling pathways, particularly those involving intracellular and extracellular RNA and DNA sensing receptors.
We hypothesize that excessive IFN-I production results from an increased tonic activation state of nucleic acid sensors and/or an enhanced responsiveness of these sensors to endogenous nucleic acids, thereby sustaining pathological IFN-I signaling and chronic inflammation.
The aim of this study is to characterize the type I interferon (IFN-I) response, defined by both the IFN-I gene signature and plasma IFN-α levels, following stimulation with a panel of ligands specific for DNA- and RNA-sensing pathways.
調査の概要
状態
介入・治療
詳細な説明
The investigators hypothesize that chronic overproduction of type I interferons (IFN-I) is driven by increased basal activation of nucleic acid-sensing pathways and/or heightened cellular responsiveness to endogenous nucleic acids, leading to sustained IFN-I signaling and persistent inflammation. The objective of the study is to characterize the IFN-I response by assessing both the interferon gene signature and plasma IFN-α levels following stimulation of PBMCs with a panel of DNA- and RNA-sensing pathway-specific ligands.
The SAFRAN study protocol comprises two study visits for patients: a mandatory Visit 1 (V1) and an optional Visit 2 (V2), the performance of which depends on the results obtained at V1. Healthy control participants will undergo Visit 1 (V1) only.
During Visit 1 (V1), the investigator will perform a clinical assessment as part of routine disease management. Disease activity will be evaluated using validated clinical scoring systems. For patients with systemic lupus erythematosus (SLE), disease activity will be assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). For patients with systemic sclerosis, skin involvement will be evaluated using the modified Rodnan Skin Score (mRSS). In addition, disease activity will be assessed in all patients using the Physician Global Assessment (PGA) scale.
During Visit 2 (V2), patients in whom an abnormality in interferon signaling is identified through the in vitro assays will undergo additional blood sampling during a routine follow-up visit conducted as part of standard clinical care. An additional blood volume of 12 mL will be collected to further characterize the abnormality detected in the previous sample (V1), within 12 months of the initial assessment.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Alexandre BELOT, MD, PhD
- 電話番号:+3342786126
- メール:Alexandre.belot@chu-lyon.fr
研究連絡先のバックアップ
- 名前:Samira PLASSART
- 電話番号:+33427855442
- メール:samira.plassart@chu-lyon.fr
研究場所
-
-
-
Bron、フランス、69500
- Hôpital Femme-Mère-Enfant
-
コンタクト:
- Alexandre BELOT, MD, Ph D
- 電話番号:+33427856126
- メール:alexandre.belot@chu-lyon.fr
-
主任研究者:
- Alexandre BELOT, MD, Ph D
-
Lyon、フランス、69003
- Hôpital Edouard Herriot
-
コンタクト:
- Thomas BARBA, MD
- 電話番号:+33472119583
- メール:thomas.barba@chu-lyon.fr
-
主任研究者:
- Thomas BARBA, MD
-
Oullins、フランス、69495
- Centre Hospitalier Lyon-Sud
-
コンタクト:
- Maël RICHARD, MD
- 電話番号:+33478843973
- メール:mael.richard@chu-lyon.fr
-
主任研究者:
- Mael RICHARD, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Patient
-
Patient followed at the Hospices Civils de Lyon (HCL) for their disease.
-
Patient aged over 6 years and under 60 years.
-
Body weight ≥ 25 kg.
-
Patient with a confirmed diagnosis of
- Systemic lupus erythematosus
- Myositis, histologically confirmed or not
- Systemic sclerosis,
- Mixed connective tissue disease, according to the Sharp or Kasukawa criteria Undifferentiated connective tissue disease, according to the criteria proposed by Mosca et al.
- Genetically confirmed monogenic lupus or monogenic interferonopathy.
-
Patient, parents, or legal guardians informed about the study and having signed the informed consent form.
Healthy Volunteer Participants
- Subjects aged over 6 years and under 60 years.
- Body weight greater than or equal to 25 kg.
- Participants, parents, or legal guardians who have been informed about the study and have provided written informed consent.
Exclusion Criteria:
Patient
- documented infection or symptoms consistent with a bacterial or viral infection within 2 weeks prior to sampling
- Subjects currently participating in an interventional drug study
- Vaccination within 1 month prior to sampling
- Pregnant, parturient, or breastfeeding women
- Individuals deprived of liberty by judicial or administrative decision
- Individuals receiving psychiatric care
- Individuals admitted to a healthcare or social care institution for reasons other than participation in the research
- Adults subject to a legal protection measure
- Individuals not affiliated with a social security scheme or not covered by an equivalent health insurance system
Healthy Volunteer Participants
- Documented infection or symptoms consistent with a bacterial or viral infection occurring within 2 weeks prior to sample collection.
- Participant with a long-term chronic disease (ALD) or any chronic medical condition.
- Participant with a primary immunodeficiency.
- Vaccination within 1 month prior to sample collection.
- History of neoplasia (< 5 years) or ongoing neoplastic disease.
- Pregnant, parturient, or breastfeeding women.
- Individuals deprived of liberty by a judicial or administrative decision.
- Individuals receiving psychiatric care.
- Individuals admitted to a health or social care institution for purposes other than participation in research.
- Adults subject to a legal protection measure (guardianship or curatorship).
- Individuals not affiliated with a social security system or not benefiting from an equivalent health insurance scheme.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Patients
Patients with systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type 1 interferonopathies |
Healthy volunteers will undergo a blood draw of a total volume of 20 mL for the following analyses: ex vivo analysis of the interferon signaling pathway (12 mL) and biological sample collection, if the patient/holder of parental authority provides consent (8 mL). |
|
他の:control
Healthy volunteer |
Healthy volunteers will undergo a blood draw of a total volume of 20 mL for the following analyses: ex vivo analysis of the interferon signaling pathway (12 mL) and biological sample collection, if the patient/holder of parental authority provides consent (8 mL). |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
IFN-I signature score
時間枠:Day 1 and Month 12 (if applicable)
|
The interferon signature assessed by transcriptomic analysis and IFN-α concentrations measured using the Simoa assay will be compared across the different disease groups and with healthy volunteers. |
Day 1 and Month 12 (if applicable)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinical phenotype
時間枠:Day 1 and Month 12 (if applicable)
|
Correlation between the extent of specific organ involvement and the activation of nucleic acid-sensing pathways, assessed by the levels of IFN-α production. |
Day 1 and Month 12 (if applicable)
|
|
plasma IFN-α concentration
時間枠:Day 1 and Month 12 (if applicable)
|
In vitro change in the IFN signature and IFN-α production in patients' PBMCs after exposure to selective inhibitors of overactivated IFN-I signaling pathways |
Day 1 and Month 12 (if applicable)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 69HCL25_0143
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。